Equities research analysts forecast that Alkermes PLC (NASDAQ:ALKS) will announce $234.90 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Alkermes PLC’s earnings, with the lowest sales estimate coming in at $233.39 million and the highest estimate coming in at $236.40 million. Alkermes PLC posted sales of $180.24 million during the same quarter last year, which would indicate a positive year over year growth rate of 30.3%. The firm is expected to report its next earnings results on Wednesday, November 1st.

On average, analysts expect that Alkermes PLC will report full year sales of $234.90 million for the current fiscal year, with estimates ranging from $888.40 million to $900.00 million. For the next fiscal year, analysts anticipate that the firm will post sales of $1.05 billion per share, with estimates ranging from $1.02 billion to $1.13 billion. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Alkermes PLC.

Alkermes PLC (NASDAQ:ALKS) last issued its quarterly earnings data on Thursday, July 27th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.01) by $0.02. The business had revenue of $218.80 million for the quarter, compared to analysts’ expectations of $216.54 million. Alkermes PLC had a negative return on equity of 9.12% and a negative net margin of 24.33%. The company’s revenue for the quarter was up 12.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.01) EPS.

A number of research firms have commented on ALKS. ValuEngine upgraded Alkermes PLC from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Leerink Swann cut Alkermes PLC from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $68.00 to $61.00 in a research note on Tuesday, June 13th. Credit Suisse Group reaffirmed a “buy” rating and issued a $70.00 price objective on shares of Alkermes PLC in a research note on Wednesday, June 7th. Cowen and Company reaffirmed a “buy” rating on shares of Alkermes PLC in a research note on Friday, April 28th. Finally, J P Morgan Chase & Co set a $78.00 price objective on Alkermes PLC and gave the company a “buy” rating in a research note on Saturday, July 1st. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $63.00.

In other news, SVP Michael J. Landine sold 10,000 shares of the business’s stock in a transaction dated Thursday, May 18th. The stock was sold at an average price of $57.23, for a total value of $572,300.00. Following the completion of the sale, the senior vice president now directly owns 167,370 shares of the company’s stock, valued at approximately $9,578,585.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Paul J. Mitchell sold 1,500 shares of the business’s stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $54.91, for a total value of $82,365.00. Following the completion of the sale, the director now directly owns 9,500 shares of the company’s stock, valued at $521,645. The disclosure for this sale can be found here. Insiders have sold a total of 99,500 shares of company stock valued at $5,776,365 over the last ninety days. 5.34% of the stock is owned by company insiders.

Several hedge funds have recently bought and sold shares of the stock. Daiwa SB Investments Ltd. purchased a new stake in Alkermes PLC during the second quarter valued at $166,000. Greenwood Capital Associates LLC increased its stake in Alkermes PLC by 2.4% in the first quarter. Greenwood Capital Associates LLC now owns 3,729 shares of the company’s stock valued at $218,000 after buying an additional 89 shares in the last quarter. Mn Services Vermogensbeheer B.V. increased its stake in Alkermes PLC by 5.9% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 4,053 shares of the company’s stock valued at $222,000 after buying an additional 224 shares in the last quarter. US Bancorp DE increased its stake in Alkermes PLC by 366.4% in the second quarter. US Bancorp DE now owns 3,974 shares of the company’s stock valued at $231,000 after buying an additional 3,122 shares in the last quarter. Finally, Insight Capital Research & Management Inc. bought a new stake in Alkermes PLC during the second quarter valued at approximately $232,000. 97.41% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “$234.90 Million in Sales Expected for Alkermes PLC (ALKS) This Quarter” was published by Watch List News and is the property of of Watch List News. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://www.watchlistnews.com/234-90-million-in-sales-expected-for-alkermes-plc-alks-this-quarter/1467785.html.

Alkermes PLC (NASDAQ:ALKS) opened at 52.38 on Thursday. The stock’s 50 day moving average price is $57.10 and its 200 day moving average price is $57.33. The company’s market cap is $8.05 billion. Alkermes PLC has a 52-week low of $41.93 and a 52-week high of $63.40.

About Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Get a free copy of the Zacks research report on Alkermes PLC (ALKS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.